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IN THE DEVELOPMENTS in organ transplantation and hepatic surgical treatment of the last quarter cen-
tury, Loyal Davis played a peripheral, but by no means insignificant or passive, role. During the first 
part of this period, Doctor Davis was chairman of the Department of Surgery at Northwestern 
University, and throughout almost all of it, he was Editor-in-Chief of SURGERY, GYNECOLOGY AND 
OBSTETRICS. The fact that he functioned in these two powerful administrative positions in an intel-
ligent and creative way was part of the explanation for his long tenure in both offices. 
In these reminiscences about Doctor Davis, I will focus upon the five year period from 1958 to 
1963, even though our acquaintance was more than casual for a decade before this time and for all the 
years after. Between 1947 and 1952, I had been a student in the M.D. and Ph.D. programs at North-
western. I met Doctor Davis within the first week of my arrival in Chicago. He was a terrifying figure 
to many of the students. He developed an interest in me because he realized that I was working toward 
a Ph.D. in neuroanatomy as well as trying to go to medical school. In my senior year, I spent my sur-
gical clerkship at Passavant Hospital on Doctor Davis' service and learned more about surgery during 
those three months than in any other similar period of my life. 
I graduated from medical school in 1952, spent the next six years in Baltimore, Maryland, and 
Miami, Florida, and returned to Northwestern in July 1958 for a one year appointment as chief res-
ident in thoracic surgery. After this, I joined the faculty as the second full-time appointee in the 
Department of Surgery of which Doctor Davis was chairman. Doctor F. John Lewis, the cardiac sur-
geon, had been the first such appointee in a department that previously had depended upon the con-
tributions of volunteer faculty to train students and house officers. 
The recruitment of surgeons for whom the medical school provided a base salary was a policy 
change which created understandable political problems for Doctor Davis. These concerned the extent 
to which the so-called full-time faculty members, who were viewed by many as tainted from university 
subsidization, should be allowed to compete for private patients who needed conventional surgical 
care. 
In defusing the situation, Doctor Davis made clear to me his desire that I develop a major and visi-
ble program in laboratory investigation. The result was an unparalleled opportunity to begin work in 
several seemingly esoteric areas that have occupied my attention for almost all of the 25 years since 
then. Even though he was a neurosurgeon, Doctor Davis watched carefully the work that was going 
on in the laboratory. For more than two decades subsequently, he kept close track ofthe developments 
which he realized had had their genesis under his original sponsorship. 
HEPATOTROPHIC FACTORS AND SURGERY OF THE LIVER 
Compared with today, grantsmanship in 1958 was a primitive and ingenuous art form. During that 
year, while still a thoracic surgical resident under Doctor F. John Lewis, I sent a four page grant ap-
plication to the National Institutes of Health requesting funds of about $30,000 a year for five years. 
The objectives were to investigate if insulin had different effects if it was given by the portal versus the 
systemic venous system, to study the effect of endogenous insulin upon the liver and its metabolism and 
to look at the possibility of ameliorating disorders of insulin and carbohydrate metabolism by portal 
diversion procedures. The money was awarded. 
In retrospect, it is surprising that support was provided. The rationale for the proposal was coun-
tercurrent to the prevailing opinion which held that portal venous blood contained no specific sub-
stances that distinguished it in an important way from other kinds of venous blood. Complications, 
such as encephalopathy, were well known to occur after portacaval shunt in dogs or in humans, but 
these were thought to be the consequences of loss of volume of hepatic blood flow after portal diversion 
rather than the loss of special portal constituents. The underlying assumption in the grant request was 
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radically different. It suggested that splanchnic venous blood returning from the nonhepatic splanch-
nic viscera was capable in a special way of influencing hepatic structure and function. In later years, 
this concept became known as the hepatotrophic hypothesis. 
No support could be found in the Northwestern laboratories for the hepatotrophic hypothesis for 
the simple reason that appropriate experimental models had not yet been developed with which to test 
the theory. Yet, Doctor Davis always remembered the original question. As the pieces fit into place 
showing, first, that portal venous blood had specific liver supporting qualities and, second, that these 
qualities were due to hormones (especially insulin) coming from the nonhepatic splanchnic organs, he 
published the evidence in SURGERY, GYNECOLOGY AND OBSTETRICS. He lived long enough to see hepa-
totrophic physiology become a defined field of research with numerous implications in clinical 
medicine (1). 
One afternoon in 1959, Doctor Davis asked me to his office and asked a number of questions about 
the conditioning which my animals had gone through before their use in experiments. He was also 
concerned about the postoperative dietary management. The chairman of biochemistry at North-
western, Doctor Smith Freeman, had been studying various aspects of the metabolism of Eck's fistula. 
Doctor Davis told me that he had been discussing my work with Doctor Freeman and that, as a con-
sequence, he was raising the issues of animal preparation and maintenance in an effort to be helpful. 
After that, he made a number of visits to the kennels on the 14th floor which resulted in a sharp in-
crease in the attention paid by the deiners to details of care. 
TRANSPLANTATION OF THE LIVER 
In order to pursue some of the inquiries about hepatic physiology which were on my mind in 1958, 
it was necessary to have a reproducible experimental preparation of total hepatectomy. I developed a 
method for use in dogs that differed from any previously reported technique in that the retrohepatic 
vena cava was left intact. The portal system was connected by vascular anastomosis to the vena cava. 
The procedure has become widely used in laboratory experimentation. In addition, it was realized as a 
direct consequence of these efforts that it might be possible to replace the extirpated liver with a hepat-
ic homograft. Many of the technical details of total hepatectomy and transplantation were similar, in-
cluding the use of a venovenous bypass from the lower to the upper half of the body of the animal 
which allowed temporary decompression of the surgically connected portal and systemic venous 
beds. 
In the summer of 1958, the first efforts at orthotopic hepatic transplantation (hepatic replacement) 
were made in dogs. The project would have discouraged a more experienced or intelligent investigator, 
since the first 27 procedures resulted in operative deaths of the recipients. However, the two principles 
essential for success were finally worked out. One was protection of the venous beds of the intestine, 
kidneys and hindquarters during the period of venous occlusion as the new liver was inserted; this was 
accomplished by more efficient venovenous bypasses. The other principle, effective graft preservation, 
was met by core-cooling the liver with cold lactated Ringer's solution. This simple preservation tech-
nique became standard for laboratory transplantation research with other organs and in clinical renal 
transplan tation. 
Once the technical principles essential for success had been defined (2), the operation of hepatic re-
placement could be studied in detail. Methods could be tested for the prevention of the rejection 
process which was the next great barrier to be surmounted. In the Chicago series of untreated canine 
liver recipients, the maximum survival period before death from rejection was 20 and a half 
days. 
Efforts to prevent rejection with total body irradiation of the recipient (or of the graft) were com-
pletely unsuccessful. It was not until 1963, after I had moved to the University of Colorado, that 
prolonged survival periods were achieved using drug therapy with azathioprine. In 1964 and 1965, 
animals which were treated with this drug or later with antilymphocyte globulin began postoperative 
lives that lasted more than a decade and were terminated by old age. 
At Doctor Davis' suggestion, the results of the experimental studies on transplantation of the liver 
from the Northwestern laboratories were published in SURGERY; GYNECOLOGY AND OBSTETRICS (2). 
It could not have been too suprising to him in the autumn of 1963 to receive a report of the first clinical 
trials with this procedure; he accepted the article for publication by return mail (3). Replacement of 
the liver has become an increasingly successful way of treating end stage hepatic disease (4, 5). 
Starzl: FESTSCHRIFT 
TRANSPLANTATION OF THE KIDNEY 
During the Chicago period of 1958 until 1961, liver transplantation received major attention from 
me because of its unique and challenging technical requirements. At the same time, we were conduct-
ing experiments with renal, splenic and composite organ grafts. These efforts were known to Doctor 
William R. Waddell, who was recruited as department chairman from Harvard to the University of 
Colorado in July 1961. Doctor Waddell asked me to join him and to become the Chief of Surgery at 
the Denver Veterans Administration Hospital which I did in December 1961. About a month earlier, 
Doctor Waddell persuaded one of the internists at Colorado who had a patient with advanced renal 
failure and a possible identical twin donor to hold this potential transplant recipient until my arrival. 
Within a month, the first of the Colorado renal transplants was carried out for the patient. This was 
not a major achievement since there was not an immunologic barrier, but within a little more than a 
year, ten more patients had been treated, all with nontwin donors. When I left Colorado 19 years 
later, six of the 11 recipients were still alive. 
The excitement of those days is hard to imagine for those who were not there. Before then, azathio-
prine had been used clinically by Murray and associates (6) in a few instances, but as a single agent, 
the drug did not prevent rejection consistently or even in a significant number of patients. The litera-
ture about renal homotransplantation was uniformly pessimistic. The patients treated in Colorado 
were the first to have the double drug therapy of azathioprine and prednisone systematically which 
became the worldwide standard for immunosuppression. With the use of these synergistic agents, an 
avalanche of new information was forthcoming about the reversibility of rejection, the "adaptation" 
that occurs after successful transplantation and a multitude of other important events (7). 
In the late spring of 1963, a manuscript about this early experience was submitted to the Journal of 
the American Medical Association. As a courtesy, I sent Doctor Davis a copy. He recognized the po-
tential importance of the observations and wrote back some opinions that reflected his maturity and 
wisdom. For one thing, he correctly predicted that the paper would be judged to be so radical and con-
trary to prevailing opinions that, if it were published at all, it would be only after major and time-
consuming editorial reviews and revisions. This proved to be the case. The manuscript sent to JAMA 
was not published until the spring of 1964. Doctor Davis also suggested that the material should be 
refined, made more highly focused and brought up to date. If these conditions were met, he offered to 
consider a streamlined version for SURGERY, GYNECOLOGY AND OBSTETRICS. 
We followed his advice. He published the article in the October 1963 issue of SURGERY, GYNE-
COLOGY AND OBSTETRICS. Its title was "The Reversal of Rejection in Human Renal Homografts with 
the Subsequent Development of Homograft Tolerance" (8). The other authors were Thomas L. 
Marchioro, now Professor of Surgery at the University of Washington, Seattle, and William R. 
Waddell. Three years later, when antilymphocyte globulin (ALG) was introduced clinically as an 
adjunct to azathioprine and prednisone in what became known as triple drug therapy, the paper was 
sent to Doctor Davis and was published in SURGERY, GYNECOLOGY AND OBSTETRICS (9). Other major 
developments in immunosuppression in the succeeding years, including the first American trials of cy-
dosporine and steroids in 1979 and 1980 (10), followed the same publication pathway. 
When Doctor Davis died, I had known him for 35 years. After I left Chicago, I wrote or called him 
several times a year, and until the last two or three years, I always made it a point to meet him at the 
party given by W. B. Saunders Company at the American College of Surgeons for what for me was an 
important critique of the past year. As he became old, his attendance there became irregular, but when 
he did not come, he always wrote and apologized. I did the same. I made no major decision in my 
professional life without consulting him first. During all this time, I never called him by his first name. 
It was a matter of respect. To some people who did not know Doctor Davis well, he was a hard and 
unyielding person. I did not see him that way. 
REFERENCES 
1. STARZL, T. E., and TERBLANCHE,J. Hepatotrophic substances. In: Progress in Liver Diseases. Edited by H. Popper and 
F. Schaffner. Vol. VI, pp. 135-152. New York: Grune & Stratton, 1979. 
2. STARZL, T. E., KAUPp, H. A., BROCK, D. R., and others. Reconstructive problems in canine liver homotransplantation 
with special reference to the postoperative role of hepatic venous flow. Surg. Gynecol. Obstet., 1960, 111: 733-743. 
3. STARZL, T. E., MARCHIORO, T. L., VON KAULLA, K., and others. Homotransplantation of the liver in humans. Surg. 
Gynecol. Obstet., 1963,117: 659-676. 
4. STARZL, T. E. Experience in Hepatic Transplantation. (With the assistance of C. W. Putnam.) Philadelphia: W. B. 
Saunders Co., 1969. 
Surgery, dynecoi~gy &- Obstetrics' August 1983 . Volume 157 
5. STARZL, T. E., IWATSUKI, S., VAN THIEL, D. H., and others. Evolution of liver transplantation. Hepatology, 1982, 2: 
614-636. 
6. MURRAY, J. E., MERRILL, J. P., DAMMIN, G. H., and others. Kidney transplantation in modified recipients. Ann. Surg., 
1962, 156: 337-355. 
7. STARZL, T. E. Experience in Renal Transplantation. Philadelphia: W. B. Saunders Co., 1964. 
8. STARZL, T. E., MARCHIORO, T. L., and WADDELL, W. R. The reversal of rejection in human renal homografts with sub-
sequent development of homograft tolerance. Surg. Gynecol. Obstet., 1963, 117: 385-395. 
9. STARZL, T. E., MARCHIORO, T. L., PORTER, K. A., and others. The use of heterologous antilymphoid agents in canine 
renal and liver homotransplantation and in human renal homotransplantation. Surg. Gynecol. Obstet., 1967, 124: 301-
318. . 
to. STARZL, T. E., WElL III, R., IWATSUKI, S., and others. The use of cyclosporin A and prednisone in cadaver kidney trans-
plantation. Surg. Gynecol. Obstet., 1980, 151: 17-26. 
